PRELUDE THERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PRELUDE THERAPEUTICS INC (PRLD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.25 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 683.50K shares, a 156.95% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.57M shares, a 7.28% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 197.28K shares, a 114.44% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.79M shares, a 3.35% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.92M shares, a 21.12% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.24M shares, a 16.62% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.88M shares, a 49.39% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 683.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 4.25M shares 10-Q · filed 2026-08-11 | 4.45M shares derived: sum of 3 quarters · filed 2026-08-11 | 4.45M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 3.57M shares 10-Q · filed 2026-05-12 | 3.77M shares derived: sum of 2 quarters · filed 2026-05-12 | 3.77M shares derived: sum of 3 quarters · filed 2026-05-12 | 4.03M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 197.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 197.28K shares derived: sum of 2 quarters · filed 2026-03-10 | 463.29K shares derived: sum of 3 quarters · filed 2026-03-10 | 3.79M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 266.00K shares derived: sum of 2 quarters · filed 2025-11-12 | 3.59M shares 10-Q · filed 2025-11-12 | 3.69M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-06-30 | 266.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 3.59M shares 10-Q · filed 2025-08-14 | 3.69M shares derived: sum of 3 quarters · filed 2026-03-10 | 3.79M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-03-31 | 3.33M shares 10-Q · filed 2025-05-06 | 3.42M shares derived: sum of 2 quarters · filed 2026-03-10 | 3.53M shares derived: sum of 3 quarters · filed 2026-03-10 | 4.18M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | 92.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 200.50K shares derived: sum of 2 quarters · filed 2026-03-10 | 851.50K shares derived: sum of 3 quarters · filed 2026-03-10 | 3.92M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 108.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 759.50K shares derived: sum of 2 quarters · filed 2024-11-06 | 3.83M shares 10-Q · filed 2024-11-06 | 3.98M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | 651.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 3.72M shares 10-Q · filed 2024-08-12 | 3.87M shares derived: sum of 3 quarters · filed 2025-03-10 | 3.98M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | 3.07M shares 10-Q · filed 2024-05-07 | 3.22M shares derived: sum of 2 quarters · filed 2025-03-10 | 3.33M shares derived: sum of 3 quarters · filed 2025-03-10 | 3.62M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | 147.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 261.00K shares derived: sum of 2 quarters · filed 2025-03-10 | 547.00K shares derived: sum of 3 quarters · filed 2025-03-10 | 3.24M shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 114.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 400.00K shares derived: sum of 2 quarters · filed 2023-11-01 | 3.09M shares 10-Q · filed 2023-11-01 | 3.72M shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-06-30 | 286.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.98M shares 10-Q · filed 2023-08-03 | 3.60M shares derived: sum of 3 quarters · filed 2024-02-15 | 4.16M shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-03-31 | 2.69M shares 10-Q · filed 2023-05-08 | 3.32M shares derived: sum of 2 quarters · filed 2024-02-15 | 3.87M shares derived: sum of 3 quarters · filed 2024-02-15 | 4.93M shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-12-31 | 626.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 1.18M shares derived: sum of 2 quarters · filed 2024-02-15 | 2.24M shares derived: sum of 3 quarters · filed 2024-02-15 | 3.88M shares 10-K · filed 2024-02-15 |
| 2022-09-30 | 552.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.61M shares derived: sum of 2 quarters · filed 2022-11-14 | 3.26M shares 10-Q · filed 2022-11-14 | 3.63M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | 1.06M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 2.71M shares 10-Q · filed 2022-08-09 | 3.08M shares derived: sum of 3 quarters · filed 2023-03-15 | 4.88M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | 1.65M shares 10-Q · filed 2022-05-10 | 2.02M shares derived: sum of 2 quarters · filed 2023-03-15 | 3.82M shares derived: sum of 3 quarters · filed 2023-03-15 | 4.13M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | 371.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 2.18M shares derived: sum of 2 quarters · filed 2023-03-15 | 2.48M shares derived: sum of 3 quarters · filed 2023-03-15 | 2.60M shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 1.81M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 2.11M shares derived: sum of 2 quarters · filed 2021-11-12 | 2.23M shares 10-Q · filed 2021-11-12 | 2.42M shares derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | 307.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 423.39K shares 10-Q · filed 2021-08-12 | 614.89K shares derived: sum of 3 quarters · filed 2022-03-17 | |
| 2021-03-31 | 115.58K shares 10-Q · filed 2021-05-11 | 307.07K shares derived: sum of 2 quarters · filed 2022-03-17 | ||
| 2020-12-31 | 191.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 4.79M shares 10-K · filed 2022-03-17 | ||
| 2020-09-30 | 4.59M shares 10-Q · filed 2020-11-10 | |||
| 2019-12-31 | 1.70M shares 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |